Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Leyi Lin

Showing results (11-20 of 19) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
The American Journal of Tropical Medicine and Hygiene|March 4, 2020
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Diaz, Michael Koren, Leyi Lin, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.
The Journal of Infectious Diseases|June 24, 2020
A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge StrainTimothy P Endy, Dongliang Wang, Mark E Polhemus, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
Vaccine|February 14, 2022
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adultsKristopher M Paolino, Jason A Regules, James E Moon, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 2

Showing results (11-20 of 19) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 19 results.
The American Journal of Tropical Medicine and Hygiene|July 19, 2017
Phase 1 Randomized Study of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults in the United StatesAlexander C Schmidt, Leyi Lin, Luis J Martinez, et al.
The American Journal of Tropical Medicine and Hygiene|March 4, 2020
Safety and Immunogenicity of Different Formulations of a Tetravalent Dengue Purified Inactivated Vaccine in Healthy Adults from Puerto Rico: Final Results after 3 Years of Follow-Up from a Randomized, Placebo-Controlled Phase I StudyClemente Diaz, Michael Koren, Leyi Lin, et al.
The American Journal of Tropical Medicine and Hygiene|April 29, 2020
Safety and Immunogenicity of an AS03<sub>B</sub>-Adjuvanted Inactivated Tetravalent Dengue Virus Vaccine Administered on Varying Schedules to Healthy U.S. Adults: A Phase 1/2 Randomized StudyLeyi Lin, Kirsten E Lyke, Michael Koren, et al.
The American Journal of Tropical Medicine and Hygiene|July 8, 2015
Safety and Immunogenicity of a Dengue Virus Serotype-1 Purified-Inactivated Vaccine: Results of a Phase 1 Clinical TrialLuis Javier Martinez, Leyi Lin, Jason M Blaylock, et al.
The Journal of Infectious Diseases|June 24, 2020
A Phase 1, Open-Label Assessment of a Dengue Virus-1 Live Virus Human Challenge StrainTimothy P Endy, Dongliang Wang, Mark E Polhemus, et al.
The Journal of Infectious Diseases|September 23, 2020
Immunogenicity of a Live-Attenuated Dengue Vaccine Using a Heterologous Prime-Boost Strategy in a Phase 1 Randomized Clinical TrialLeyi Lin, Michael A Koren, Kristopher M Paolino, et al.
Vaccine|February 14, 2022
Safety and immunogenicity of a plant-derived recombinant protective antigen (rPA)-based vaccine against Bacillus anthracis: A Phase 1 dose-escalation study in healthy adultsKristopher M Paolino, Jason A Regules, James E Moon, et al.
The Lancet. Infectious Diseases|June 30, 2023
Safety and immunogenicity of a purified inactivated Zika virus vaccine candidate in adults primed with a Japanese encephalitis virus or yellow fever virus vaccine in the USA: a phase 1, randomised, double-blind, placebo-controlled clinical trialMichael A Koren, Leyi Lin, Kenneth H Eckels, et al.
Lancet (London, England)|December 9, 2017
Preliminary aggregate safety and immunogenicity results from three trials of a purified inactivated Zika virus vaccine candidate: phase 1, randomised, double-blind, placebo-controlled clinical trialsKayvon Modjarrad, Leyi Lin, Sarah L George, et al.
Pageof 2